An Open-Label, Single-Arm Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Ivonescimab in the Perioperative Treatment of Cisplatin-Ineligible Muscle-Invasive Bladder Cancer (MIBC)
Latest Information Update: 10 May 2025
At a glance
- Drugs Disitamab vedotin (Primary) ; Ivonescimab (Primary)
- Indications Bladder cancer
- Focus Therapeutic Use
Most Recent Events
- 10 May 2025 New trial record